FindTrial
Sign In

Clinical efficacy and cost effectiveness analysis of tranexamic and aminocaproic acids for perioperative transfusion reduction in total hip arthroplasty

Clinical efficacy and cost effectiveness analysis of tranexamic and aminocaproic acids for perioperative transfusion reduction in total hip arthroplasty: A retrospective study of Chinese patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055332
Enrollment
Unknown
Registered
2022-01-07
Start date
2019-01-01
Completion date
Unknown
Last updated
2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total hip arthroplasty

Interventions

TXA group:Receive topical combined with intravenous tranexamic acid
EACA group:Receive topical combined with intravenous epsilon aminocaproic acid
Control group:Placebo

Sponsors

Affiliated Zhongshan Hospital of Dalian University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who underwent primary total hip arthroplasty in our hospital from January 2019 to December 2020.

Exclusion criteria

Exclusion criteria: Those with chronic heart failure or ischaemic heart disease, chronic hepatic or renal failure, thromboembolic episodes, a history of hip surgery, idiopathic osteonecrosis of the femoral head, rheumatoid arthritis, or a preoperative haemoglobin (HGB) level below 8 g/dL were excluded.

Design outcomes

Secondary

MeasureTime frame
operation time;postoperative complications;length of hospital stay;—

Primary

MeasureTime frame
estimated perioperative blood loss;transfusions;transfusions-related cost per patient;drops in HGB and HCT levels;—

Countries

China

Contacts

Public ContactXie Hui

Affiliated Zhongshan Hospital of Dalian University

xiehui424@163.com+86 15942836721

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026